logo

Dicerna Pharmaceuticals, Inc. (DRNA)



Trade DRNA now with
  Date
  Headline
9/16/2020 7:33:21 AM Dicerna Appoints Ling Zeng As Chief Legal Officer And Secretary
6/18/2020 7:38:12 AM Dicerna Receives Rare Pediatric Disease Designation From FDA For Nedosiran For Treatment Of Primary Hyperoxaluria
4/30/2020 4:40:57 PM Terex Q1 Loss/share $0.35 Vs. Loss $0.93 Year Ago
4/6/2020 7:08:39 AM Alnylam, Dicerna Form Collaboration On Investigational RNAi Therapeutics For Treatment Of Alpha-1 Liver Disease
3/31/2020 7:41:40 AM Dicerna Provides Initial Observations From PHYOX3 Trial Of Nedosiran For Primary Hyperoxaluria Dicerna Pharma
2/10/2020 7:33:20 AM Dicerna Appoints Stephen Doberstein To Board
1/2/2020 7:35:48 AM Dicerna Reports Closing Of Deal With Novo Nordisk For Development Of RNAi For Liver-Related Cardio-Metabolic Diseases
12/19/2019 7:33:43 AM Dicerna(tm) Announces Closing Of Worldwide Collaboration And Licensing Agreement With Roche
12/17/2019 7:35:31 AM Dicerna Gets Orphan Drug Designation From EC For DCR-A1AT For Congenital Alpha-1 Antitrypsin Deficiency
11/18/2019 6:02:31 AM Dicerna, Novo Nordisk To Discover, Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases
9/19/2019 4:07:20 PM Dicerna Appoints Patrick Gray To Board Of Directors
7/15/2019 7:36:54 AM Dicerna Receives Breakthrough Therapy Designation For DCR-PHXC For Treatment Of Primary Hyperoxaluria Type 1
6/20/2019 7:34:31 AM Dicerna Pharma Appoints Bernd Hoppe As VP, Global Medical Affairs, Effective July 1
3/29/2019 6:36:26 AM Dicerna Announces Presentation Of Updated Data Demonstrating Utility Of DCR-PHXC In Treating PH1 And PH2